Hepatic - Colorectal Metastasis - Pipeline Insight, 2024

Hepatic - Colorectal Metastasis - Pipeline Insight, 2024

DelveInsight’s, “Hepatic - Colorectal Metastasis - Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Hepatic - Colorectal Metastasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Hepatic - Colorectal Metastasis: Understanding

Hepatic - Colorectal Metastasis: Overview

Colorectal cancer (CRC) is one of the most frequently occurring malignancy tumors with a high morbidity additionally, CRC patients may develop liver metastasis, which is the major cause of death. Despite significant advances in diagnostic and therapeutic techniques, the survival rate of colorectal liver metastasis (CRLM) patients remains very low. CRLM, as a complex cascade reaction process involving multiple factors and procedures, has complex and diverse molecular mechanisms. Hepatic-colorectal metastasis refers to the spread of colorectal cancer cells to the liver. Colorectal cancer commonly metastasizes to the liver due to its proximity and the hepatic blood supply. This process usually occurs through the bloodstream or lymphatic system, as cancer cells break away from the primary tumor in the colon or rectum and travel to the liver, where they establish secondary tumors. Hepatic-colorectal metastasis significantly impacts prognosis and treatment options for individuals with colorectal cancer, as liver involvement often signifies advanced disease.

The management of hepatic-colorectal metastasis typically involves a multidisciplinary approach, including surgery, chemotherapy, targeted therapy, and possibly radiation therapy. Surgical resection of liver metastases can be curative in some cases, particularly when the metastases are limited in number and size. Chemotherapy, both before and after surgery, aims to shrink tumors, prevent recurrence, and improve overall survival rates. Targeted therapies, such as monoclonal antibodies and kinase inhibitors, may also be used to specifically target cancer cells while minimizing damage to healthy tissues.

""Hepatic - Colorectal Metastasis- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatic - Colorectal Metastasis pipeline landscape is provided which includes the disease overview and Hepatic - Colorectal Metastasis treatment guidelines. The assessment part of the report embraces, in depth Hepatic - Colorectal Metastasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatic - Colorectal Metastasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hepatic - Colorectal Metastasis R&D. The therapies under development are focused on novel approaches to treat/improve Hepatic - Colorectal Metastasis.

Hepatic - Colorectal Metastasis Emerging Drugs Chapters

This segment of the Hepatic - Colorectal Metastasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hepatic - Colorectal Metastasis Emerging Drugs

Sotevtamab: Alethia Biotherapeutics

Sotevtamab is a humanized, immunoglobulin (Ig) G2 monoclonal antibody against the secreted form of human clusterin (sCLU) expressed by tumor cells, with potential antineoplastic and anti-metastatic activities. Upon administration, anti-sCLU monoclonal antibody AB-16B5 specifically binds to tumor-associated sCLU and inhibits its activity. This inhibits both the sCLU-mediated signal transduction pathways and epithelial-to-mesenchymal transition (EMT), which leads to the inhibition of tumor cell migration and invasion. In addition, AB-16B5 enhances chemo-sensitivity. sCLU, a heterodimeric disulfide-linked glycoprotein overexpressed by various types of cancer cells, contributes to proliferation and survival of cancer cells, and stimulates tumor cell EMT. The drug is currently in Phase II stage of clinical trial evaluation for the treatment of Hepatic Colorectal Metastasis.

Further product details are provided in the report……..

Hepatic - Colorectal Metastasis: Therapeutic Assessment

This segment of the report provides insights about the different Hepatic - Colorectal Metastasis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hepatic - Colorectal Metastasis

There are approx. 3+ key companies which are developing the therapies for Hepatic - Colorectal Metastasis. The companies which have their Hepatic - Colorectal Metastasis drug candidates in the most advanced stage, i.e. Phase II include, Alethia Biotherapeutics.

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Hepatic - Colorectal Metastasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hepatic - Colorectal Metastasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatic - Colorectal Metastasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatic - Colorectal Metastasis drugs.

Hepatic - Colorectal Metastasis Report Insights

Hepatic - Colorectal Metastasis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Hepatic - Colorectal Metastasis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Hepatic - Colorectal Metastasis drugs?

How many Hepatic - Colorectal Metastasis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatic - Colorectal Metastasis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hepatic - Colorectal Metastasis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Hepatic - Colorectal Metastasis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Alethia Biotherapeutics

Amal Therapeutics

Key Products

Sotevtamab

ATP128